EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Therapeutic strategy for Fabry disease by intravenous administration of adeno‐associated virus 2 or 9 in α‐galactosidase A‐deficient mice

Yuka Hayashi, Yoshihide Sehara iD, Ryota Watano, Kenji Ohba iD, Yuki Takayanagi iD, Kazuhiro Muramatsu iD, Yoshio Sakiyama iD, Hiroaki Mizukami iD

The Journal of Gene Medicine · 2023-12 · 25 (12)

DOI: 10.1002/jgm.3560 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, online erschienen am 30.06.2023. Verfasst von Yuka Hayashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSPS KAKENHI, AMED, Ichiro Kanehara Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fabry disease (FD) is an inherited lysosomal storage disease caused by deficiency of α‐galactosidase A (α‐Gal A) encoded by the GLA gene. The symptoms of FD occur as a result of the accumulation of globotriaosylceramide (Gb3), comprising a substrate of α‐Gal A, in the organs. Adeno‐associated virus (AAV)‐mediated gene therapy is a promising treatment for FD. Methods α‐Gal A knockout (GLAko) mice were injected intravenously with AAV2 (1 × 10 11 viral genomes [vg]) or AAV9 (1 × 10 11 or 2 × 10 12 vg) vectors carrying human GLA (AAV‐hGLA), and plasma, brain, heart, liver and kidney were tested for α‐Gal A activity. The vector genome copy numbers (VGCNs) and Gb3 content in each organ were also examined.

Results

The plasma α‐Gal A enzymatic activity was three‐fold higher in the AAV9 2 × 10 12 vg group than wild‐type (WT) controls, which was maintained for up to 8 weeks after injection. In the AAV9 2 × 10 12 vg group, the level of α‐Gal A expression was high in the heart and liver, intermediate in the kidney, and low in the brain. VGCNs in the all organs of the AAV9 2 × 10 12 vg group significantly increased compared to the phosphate‐buffered‐saline (PBS) group. Although Gb3 in the heart, liver and kidney of the AAV9 2 × 10 12 vg was reduced compared to PBS group and AAV2 group, and the amount of Gb3 in the brain was not reduced.

Conclusions

Systemic injection of AAV9‐hGLA resulted in α‐Gal A expression and Gb3 reduction in the organs of GLAko mice. To expect a higher expression of α‐Gal A in the brain, the injection dosage, administration route and the timing of injection should be reconsidered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry Diseasealpha-GalactosidaseAdministration, IntravenousMice, KnockoutHumansDependovirusMiceAnimals

Stichwörter der Autor:innen

Fabry diseaseadeno-associated virus vectorgene therapymousesystemic administrationα-galactosidase A deficiency

Substanzen

alpha-Galactosidase

Autor:innen und Institutionen

  • Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan.
  • Department of Neurology, Jichi Medical University Saitama Medical Center, Omiya, Japan.
  • Division of Brain and Neurophysiology, Department of Physiology, Jichi Medical University, Shimotsuke, Japan.
  • Department of Pediatrics, Jichi Medical University, Shimotsuke, Japan.

ORCID-Profile: Yoshihide Sehara, Kenji Ohba, Yuki Takayanagi, Kazuhiro Muramatsu, Yoshio Sakiyama, Hiroaki Mizukami

Förderung

  • JSPS KAKENHI
  • AMED
  • Ichiro Kanehara Foundation
  • Taiju Life Social Welfare Foundation
  • Japan Brain Foundation
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care

Zitieren

APA

Hayashi, Y., Sehara, Y., Watano, R., Ohba, K., Takayanagi, Y., Muramatsu, K., Sakiyama, Y., & Mizukami, H. (2023). Therapeutic strategy for Fabry disease by intravenous administration of adeno‐associated virus 2 or 9 in α‐galactosidase A‐deficient mice. The Journal of Gene Medicine, 25(12). https://doi.org/10.1002/jgm.3560

Vancouver

Hayashi Y, Sehara Y, Watano R, Ohba K, Takayanagi Y, Muramatsu K, et al. Therapeutic strategy for Fabry disease by intravenous administration of adeno‐associated virus 2 or 9 in α‐galactosidase A‐deficient mice. The Journal of Gene Medicine. 2023;25(12). doi:10.1002/jgm.3560

BibTeX
@article{Hayashi2023,
  author = {Hayashi, Yuka and Sehara, Yoshihide and Watano, Ryota and Ohba, Kenji and Takayanagi, Yuki and Muramatsu, Kazuhiro and Sakiyama, Yoshio and Mizukami, Hiroaki},
  title = {Therapeutic strategy for Fabry disease by intravenous administration of adeno‐associated virus 2 or 9 in α‐galactosidase A‐deficient mice},
  journal = {The Journal of Gene Medicine},
  year = {2023},
  volume = {25},
  number = {12},
  doi = {10.1002/jgm.3560}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche